Navigation Links
First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients
Date:4/30/2009

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.

"There is a consensus among physicians that early initiation of effective therapy beginning shortly after symptom onset may be required to alter the long term course of MS, but until now there has been little evidence to support this hypothesis," said Dr. R. Philip Kinkel, director of the multiple sclerosis center, Beth Israel Deaconess Medical Center in Boston, MA and lead investigator of CHAMPIONS. "This data confirms that treatment of high risk patients beginning shortly after symptom-onset reduces relapse rates and may reduce disease progression for up to 10 years. This may translate into an ability to remain active and enjoy daily activities that otherwise might be lost without treatment."

The CHAMPIONS open label follow-up study was designed to determine long-term clinical outcomes and the ten-year follow up included 155 patients from 24 of the 50 Phase III CHAMPS study sites. Key findings include:

  • 40 percent reduction in conversion to CDMS in patients treated immediately upon diagnosis of CIS versus tho
    '/>"/>

Contact: Kathy Vigneault
kathleen.vigneault@mslworldwide.com
617-937-2546
Manning Selvage & Lee
Source:Eurekalert

Page: 1 2

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... Walk on the Capitol,is proud to announce Caitlin Van ... guest speaker for our National obesity awareness event,in Washington, ... Capitol is a,history-making awareness event that will gather thousands ... the obesity epidemic and,the need for expanded efforts in ...
... 2 ,Dawning Technologies, Inc. (Dawning) and Medical Automation ... joint project to leverage their,product synergies and create ... project will focus on the seamless integration of ... RALS(R)-,Plus POC Data Management solutions. RALS-Plus is a ...
... Merger, CHICAGO, June 2 Allscripts, the ... that,physicians use to improve healthcare, announced today that ... Act of,1976, with respect to the merger agreement ... Healthcare to form Allscripts-Misys Healthcare,Solutions, Inc., has expired., ...
... MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure ... company developing,high-value human plasma-derived protein products for ... quarter results., Financing, As a ... to-date from key,shareholders to exercise their Series ...
... care deserves more funding for estimated 2.5 million displaced ... removed from their homes due to mistreatment have fewer ... kinship care -- than if they,re placed in foster ... by researchers at Children,s Hospital of Philadelphia, looked at ...
... are similar to the type diagnosed in Sen. Edward ... experimental cancer vaccine is showing promise against the same ... Kennedy, researchers are reporting. , The vaccine, when given ... with glioblastoma multiforme tumors. Kennedy was diagnosed last month ...
Cached Medicine News:Health News:Television Star Caitlin Van Zandt Signs-on as Special Guest Speaker for National Obesity Awareness Event in Washington, DC, on June 17 2Health News:Dawning Technologies, Inc. and Medical Automation Systems, Inc. to Develop a Business Partnership 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 3Health News:Kids Living With Relatives Have Fewer Problems Than Those in Foster Homes 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 2014   Evidera , a leading provider of evidence-based ... for Drug Evaluation and Research (CDER), U.S. Food and ... document for a patient-reported outcome (PRO) measure in drug ... Tool [EXACT] for Measurement of Symptoms of Acute Bacterial ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
... 2010 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ... "Company"), which is engaged in the research, development, ... cosmetic products in the People,s Republic of China ... (the "NYSE Amex" or "Exchange") has accepted the ...
Cached Medicine Technology:Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 2NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 3
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
... rede phines sharpness and efficiency with ... penetrating keratoplasty. Advanced trephine blade technology ... achieve the critical fit needed for successful ... customized system enables surgeons to select the ...
Medicine Products: